Product Name :
UBE2C monoclonal antibody Background :
Protein ubiquitination requires the concerted action of the E1, E2, and E3 ubiquitin-conjugating enzymes. Ubiquitin is first activated through ATP-dependent formation of a thiol ester with ubiquitin-activating enzyme E1. The activated ubiquitin is then transferred to a thiol group of ubiquitin-carrier enzyme E2. The final step is the transfer of ubiquitin from E2 to an ε-amino group of the target protein lysine residue, which is mediated by ubiquitin-ligase enzyme E3. Ubiquitin-conjugating enzyme 2C (UBE2C) is one of several ubiquitin conjugating enzymes participating in the E3 anaphase-promoting complex (APC/C). UBE2C is involved in the control of multiple stages of the cell cycle including inactivation of the mitotic spindle assembly checkpoint. UBE2C facilitates ubiquitin-dependent proteasomal degradation by initiating K11-linked ubiquitin chains on APC/C substrates. Research studies show that UBE2C expression is low in normal tissues, but its expression is dramatically upregulated in tumors derived from tissues such as lung, breast, and prostate. Overexpression of UBE2C in many types of solid tumors has been attributed to genomic amplification of the UBE2C locus and research studies have suggested that inhibition of UBE2C activity may have therapeutic potential. Product :
Mouse IgG1 kappa. Liquid in PBS, pH 7.3, 30% glycerol, and 0.01% sodium azide. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
Recognizes endogenous levels of UBE2C protein. Immunogen :
KLH-conjugated synthetic peptide encompassing a sequence within the C-term region of human UBE2C. The exact sequence is proprietary. Conjugate :
Unconjugated Modification :
Unmodification
UBE2C monoclonal antibody Background :
Protein ubiquitination requires the concerted action of the E1, E2, and E3 ubiquitin-conjugating enzymes. Ubiquitin is first activated through ATP-dependent formation of a thiol ester with ubiquitin-activating enzyme E1. The activated ubiquitin is then transferred to a thiol group of ubiquitin-carrier enzyme E2. The final step is the transfer of ubiquitin from E2 to an ε-amino group of the target protein lysine residue, which is mediated by ubiquitin-ligase enzyme E3. Ubiquitin-conjugating enzyme 2C (UBE2C) is one of several ubiquitin conjugating enzymes participating in the E3 anaphase-promoting complex (APC/C). UBE2C is involved in the control of multiple stages of the cell cycle including inactivation of the mitotic spindle assembly checkpoint. UBE2C facilitates ubiquitin-dependent proteasomal degradation by initiating K11-linked ubiquitin chains on APC/C substrates. Research studies show that UBE2C expression is low in normal tissues, but its expression is dramatically upregulated in tumors derived from tissues such as lung, breast, and prostate. Overexpression of UBE2C in many types of solid tumors has been attributed to genomic amplification of the UBE2C locus and research studies have suggested that inhibition of UBE2C activity may have therapeutic potential. Product :
Mouse IgG1 kappa. Liquid in PBS, pH 7.3, 30% glycerol, and 0.01% sodium azide. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
Recognizes endogenous levels of UBE2C protein. Immunogen :
KLH-conjugated synthetic peptide encompassing a sequence within the C-term region of human UBE2C. The exact sequence is proprietary. Conjugate :
Unconjugated Modification :
Unmodification
-
Western blot analysis of UBE2C expression in 293T (A), A431 (B) whole cell lysates.
Bioworld Biotech only provide peptides for our antibodies and do not provide additional peptide customization services.
Price/Size :
USD 368/1mg/vial
Tips:
For phospho antibody, we provide phospho peptide(0.5mg) and non-phospho peptide(0.5mg).Describe :
Blocking peptides are peptides that bind specifically to the target antibody and block antibody binding. These peptide usually contains the epitope recognized by the antibody. Antibodies bound to the blocking peptide no longer bind to the epitope on the target protein. This mechanism is useful when non-specific binding is an issue, for example, in Western blotting (WB) and Immunohistochemistry (IHC). By comparing the staining from the blocked antibody versus the antibody alone, one can see which staining is specific; Specific binding will be absent from the western blot or IHC performed with the neutralized antibody.Formula:
Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 10 mg/ml.The purity is >90%,tested by HPLC and MS.
Storage:
The freeze-dried powder is more stable. For short time at 2-8°C. For long term storage store at -20°C.
Note :
This product is for research use only (RUO only). Not for use in diagnostic or therapeutic procedures.